Cargando…

Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides difficile Infection in the USA

INTRODUCTION: Recurrent Clostridioides difficile infection (rCDI) is common and associated with considerable clinical and economic consequences. REBYOTA™ (fecal microbiota, live-jslm [FMBL]) is a microbiota-based live biotherapeutic approved for the prevention of rCDI following antibiotic treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lodise, Thomas, Guo, Amy, Yang, Min, Cook, Erin E., Song, Wei, Yang, Danni, Wang, Qingyuan, Zhao, Angela, Bochan, Markian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220097/ https://www.ncbi.nlm.nih.gov/pubmed/37093359 http://dx.doi.org/10.1007/s12325-023-02505-1

Ejemplares similares

Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US
por: Lodise, Thomas, et al.
Publicado: (2023)

Safety of fecal microbiota, live-jslm (REBYOTA(™)) in individuals with recurrent Clostridioides difficile infection: data from five prospective clinical trials
por: Lee, Christine, et al.
Publicado: (2023)

Retrospective Analysis of the Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA(TM)) Administered Under Enforcement Discretion to Patients With Clostridioides difficile Infection
por: Feuerstadt, Paul, et al.
Publicado: (2023)

Effect of Fecal Microbiota, Live-Jslm (REBYOTA [RBL]) on Health-Related Quality of Life in Patients With Recurrent Clostridioides difficile Infection: Results From the PUNCH CD3 Clinical Trial
por: Garey, Kevin W, et al.
Publicado: (2023)

Economic Impact of Recurrent Clostridioides difficile Infection in the USA: A Systematic Literature Review and Cost Synthesis
por: Reveles, Kelly R., et al.
Publicado: (2023)

Two-year durability of REBYOTA™ (RBL), a live biotherapeutic for the prevention of recurrent Clostridioides difficile infections
por: Orenstein, Robert, et al.
Publicado: (2023)

702. Efficacy of Fecal Microbiota, Live-jslm After Receipt of Non–Clostridioides difficile Infection Antibiotics: Post Hoc Subgroup Analysis of a Phase 2 Open-Label Trial
por: Reveles, Kelly R, et al.
Publicado: (2023)

706. An Ad Hoc Subgroup Analysis of a Phase 3, Open-Label Study Indicates Efficacy and Safety of Fecal Microbiota, Live-jslm in Participants With Recurrent Clostridioides difficile Infection and Renal Impairment
por: Fischer, Monika, et al.
Publicado: (2023)

Fecal Microbiota of Toxigenic Clostridioides difficile-Associated Diarrhea
por: Hernández, Marta, et al.
Publicado: (2019)

Fecal microbiota transplantation beyond Clostridioides difficile infections
por: Wortelboer, Koen, et al.
Publicado: (2019)

Fecal Microbiota Transplantation beyond Clostridioides Difficile Infection
por: Moon, Chang Mo, et al.
Publicado: (2021)

Fecal microbiota transplantation for recurrent Clostridioides difficile, safety, and pitfalls
por: Sandhu, Avnish, et al.
Publicado: (2021)

Immunological mechanisms of fecal microbiota transplantation in recurrent Clostridioides difficile infection
por: Soveral, Lucas F, et al.
Publicado: (2022)

Fecal Microbiota Transplantation for Clostridioides Difficile Infection in Patients with Chronic Liver Disease
por: Meighani, Alireza, et al.
Publicado: (2020)

Fecal Microbiota Transplantation Is Effective for the Treatment of Partially Treated Clostridioides difficile Infection
por: Cho, Young-Seok
Publicado: (2021)

Factors Related to Outcomes of Fecal Microbiota Transplantation in Patients with Clostridioides difficile Infection
por: Yoon, Hyuk, et al.
Publicado: (2021)

Ischemic colitis complicated by Clostridioides difficile infection treated with fecal microbiota transplantation
por: Kang, Seok Hyung, et al.
Publicado: (2023)

467 Analysis of Clinical and Economical Outcomes of Fidaxomicin Use for Clostridium difficile infections
por: Flaherty, Sarah, et al.
Publicado: (2014)

Fecal Microbiota Transplantation for Severe or Fulminant Clostridioides difficile Infection: Systematic Review and Meta-analysis
por: Song, Yi Nong, et al.
Publicado: (2021)

Faecalibacterium prausnitzii increases following fecal microbiota transplantation in recurrent Clostridioides difficile infection
por: Björkqvist, Olle, et al.
Publicado: (2021)

Heterogeneity of Randomized Controlled Trials of Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection
por: Feuerstadt, Paul, et al.
Publicado: (2021)

Real-world Use of Bezlotoxumab and Fecal Microbiota Transplantation for the Treatment of Clostridioides difficile Infection
por: de la Villa, Sofía, et al.
Publicado: (2023)

The impact of the COVID-19 pandemic on Clostridioides difficile infection and utilization of fecal microbiota transplantation
por: Bachour, Salam P., et al.
Publicado: (2023)

Interactions Between Clostridioides difficile and Fecal Microbiota in in Vitro Batch Model: Growth, Sporulation, and Microbiota Changes
por: Horvat, Sabina, et al.
Publicado: (2018)

Investigation of Intestinal Microbiota and Fecal Calprotectin in Non-Toxigenic and Toxigenic Clostridioides difficile Colonization and Infection
por: Han, Sung-Hee, et al.
Publicado: (2020)

Fecal microbiota transplantation and donor screening for Clostridioides difficile infection during COVID-19 pandemic
por: Chiu, Cheng-Hsun, et al.
Publicado: (2021)

Ulcerative Proctitis in a Patient With a History of Fecal Microbiota Transplant for Clostridioides difficile Infection
por: Massaro, Michael, et al.
Publicado: (2020)

Changes in IgA-targeted microbiota following fecal transplantation for recurrent Clostridioides difficile infection
por: Huus, Kelsey E, et al.
Publicado: (2020)

Safety and efficacy of fecal microbiota transplantation to treat and prevent recurrent Clostridioides difficile in cancer patients
por: Ali, Hiba, et al.
Publicado: (2021)

Deep hyperammonemic hepatic encephalopathy precipitated by fecal microbiota transplantation for fulminant Clostridioides difficile infection
por: Eriksen, Lotte Lindgreen, et al.
Publicado: (2021)

Fecal microbiota transplantation can improve cognition in patients with cognitive decline and Clostridioides difficile infection
por: Park, Soo-Hyun, et al.
Publicado: (2022)

“Bacterial Consortium”: A Potential Evolution of Fecal Microbiota Transplantation for the Treatment of Clostridioides difficile Infection
por: Quaranta, Gianluca, et al.
Publicado: (2022)

Fecal Microbiota Transplantation in Patients Co-Infected with SARS-CoV2 and Clostridioides difficile
por: Boicean, Adrian, et al.
Publicado: (2022)

2235. Fecal Biomarkers for Clostridioides difficile Infection in Cancer Patients
por: Olvera, Adilene, et al.
Publicado: (2019)

Usefulness of Fecal Calprotectin in the Management of Patients with Toxigenic Clostridioides difficile
por: Suarez-Carantoña, Cecilia, et al.
Publicado: (2021)

Fecal host biomarkers predicting severity of Clostridioides difficile infection
por: Golizeh, Makan, et al.
Publicado: (2021)

Gram-Negative Taxa and Antimicrobial Susceptibility after Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection
por: Steed, Danielle Barrios, et al.
Publicado: (2020)

2432. Durability Against Antibiotics After Response to Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection
por: Saha, Srishti, et al.
Publicado: (2019)

2436. Real-world Evidence of Fecal Microbiota Transplant Use and Outcomes in Patients with Clostridioides difficile Infection
por: Nelson, Winnie, et al.
Publicado: (2019)

792. Evaluation of Persistent Diarrhea and Recurrence Following Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection
por: Boton, Noah, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_efvl1dtiqqjfuc7a812gjigi12